Sibo Tian1, Xinyan Zhang2, Renjian Jiang2, Rathi N Pillai3, Taofeek K Owonikoko3, Conor E Steuer3, Nabil F Saba3, Suchita Pakkala3, Pretesh R Patel1, Chandra P Belani4, Fadlo R Khuri3, Walter J Curran1, Suresh S Ramalingam3, Madhusmita Behera5, Kristin A Higgins6. 1. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. 2. Rollins School of Public Health, Emory University, Atlanta, GA. 3. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. 4. Department of Medicine, Penn State Hershey Cancer Institute, Hershey, PA. 5. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Department of Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA. 6. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Electronic address: kristin.higgins@emory.edu.
Abstract
BACKGROUND: The prognosis of patients with extensive-stage small-cell lung carcinoma (ES-SCLC) is poor. The benefit of consolidative thoracic radiation therapy (TRT) in ES-SCLC has been inconclusive, and its use inconsistent. The objective of this study was to evaluate overall survival (OS) of ES-SCLC patients treated with chemotherapy (CT) with or without TRT using an administrative database approach. PATIENTS AND METHODS: The National Cancer Database was queried to identify patients with ES-SCLC diagnosed between 2010 and 2014. Those with brain metastases, those who received radiotherapy before CT, or radiotherapy outside the thorax, were excluded. Propensity score-matching (PSM) was used to compare OS of patients treated with CT and TRT with those who received CT alone. Patients who received >10 radiotherapy fractions were also compared with those who received 10 or fewer. RESULTS: We included 14,367 patients in the primary analysis; 12,019 received CT alone, and 2348 received CT with TRT. In multivariate analysis, CT was associated with an increased risk of death relative to CT with TRT (hazard ratio [HR], 1.74 [95% confidence interval (CI), 1.64-1.84]; log-rank P < .001), which remained significant with PSM. Median OS was 12.1 versus 8.2 months (CT with TRT vs. CT); 12-month OS was 50.5% versus 28.5%, and 5-year OS 7.6% versus 2.0% (HR, 1.80 [95% CI, 1.67-1.95], HR P < .001). Of 3099 patients who received TRT, >10 radiotherapy fractions was associated with superior OS (HR, 1.70 [95% CI, 1.49-1.95], log-rank P < .001); this finding remained significant with PSM. CONCLUSION: Use of TRT after CT in ES-SCLC patients was associated with long-term survival; its use should be considered in addition to standard of care CT.
BACKGROUND: The prognosis of patients with extensive-stage small-cell lung carcinoma (ES-SCLC) is poor. The benefit of consolidative thoracic radiation therapy (TRT) in ES-SCLC has been inconclusive, and its use inconsistent. The objective of this study was to evaluate overall survival (OS) of ES-SCLC patients treated with chemotherapy (CT) with or without TRT using an administrative database approach. PATIENTS AND METHODS: The National Cancer Database was queried to identify patients with ES-SCLC diagnosed between 2010 and 2014. Those with brain metastases, those who received radiotherapy before CT, or radiotherapy outside the thorax, were excluded. Propensity score-matching (PSM) was used to compare OS of patients treated with CT and TRT with those who received CT alone. Patients who received >10 radiotherapy fractions were also compared with those who received 10 or fewer. RESULTS: We included 14,367 patients in the primary analysis; 12,019 received CT alone, and 2348 received CT with TRT. In multivariate analysis, CT was associated with an increased risk of death relative to CT with TRT (hazard ratio [HR], 1.74 [95% confidence interval (CI), 1.64-1.84]; log-rank P < .001), which remained significant with PSM. Median OS was 12.1 versus 8.2 months (CT with TRT vs. CT); 12-month OS was 50.5% versus 28.5%, and 5-year OS 7.6% versus 2.0% (HR, 1.80 [95% CI, 1.67-1.95], HR P < .001). Of 3099 patients who received TRT, >10 radiotherapy fractions was associated with superior OS (HR, 1.70 [95% CI, 1.49-1.95], log-rank P < .001); this finding remained significant with PSM. CONCLUSION: Use of TRT after CT in ES-SCLC patients was associated with long-term survival; its use should be considered in addition to standard of care CT.
Authors: Bin Zhou; Qiuyuan Li; Linlin Qin; Zhao Li; Kaiqi Jin; Jie Dai; Yuming Zhu; Yang Yang; Salma K Jabbour; Alfredo Tartarone; Calvin S H Ng; Alfons Navarro; Cecilia Pompili; Gening Jiang Journal: Transl Lung Cancer Res Date: 2021-10
Authors: Michael Stokes; Noami Berfeld; Alicia Gayle; Andrew Descoteaux; Oscar Rohrmoser; April Franks Journal: Medicine (Baltimore) Date: 2022-07-01 Impact factor: 1.817